The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients
- 226 Downloads
Levothyroxine supplementation is insufficient for the management of one tenth of patients with hypothyroidism. Iodothyronine deiodinases have been suggested to play a role in residual hypothyroid symptoms of these patients by controlling local thyroid hormone homeostasis. Previous research has suggested a relationship between commonly inherited variations in type 2 iodothyronine deiodinase and impaired well-being. We evaluated the prevalence of iodothyronine deiodinase genotypes and their association with psychological well-being in the Korean hypothyroid population.
A prospective observational study. We enrolled 196 hypothyroid subjects (136 chronic autoimmune thyroiditis and 60 thyroid cancer) and assessed baseline well-being using six validated questionnaires. Genotyping was conducted for 19 single nucleotide polymorphisms in type 1, 2, and 3 iodothyronine deiodinase using Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all patients.
Frequencies of iodothyronine deiodinase genotypes and well-being scores were not different in hypothyroid subjects according to their disease types. Minor genotypes of a few iodothyronine deiodinase 1 variants (rs11206244, rs2294512, and rs4926616) were associated with reduced psychological well-being. However, iodothyronine deiodinase 2 and 3 variants had no effect on baseline well-being.
Minor variations in iodothyronine deiodinase 1 were associated with decreased well-being in the Korean hypothyroid population, whereas iodothyronine deiodinase 2 and 3 were not. Due to controversial results among different ethnicities, further studies to clarify the effects of iodothyronine deiodinase polymorphisms on psychological well-being are warranted in hypothyroid individuals.
KeywordsIodothyronine deiodinase Polymorphism Hypothyroidism Psychological well-being
We thank Ponnusamy Saravanan for use of the Thyroid Symptom Questionnaire.
This study was funded by the Korean Foundation for Cancer Research (grant number CB-2011-03-02).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The study was approved by the institutional research committee and informed consent was obtained from all individual participants included in the study.
- 3.J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 24, 1670–1751 (2014). doi: 10.1089/thy.2014.0028 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.B. Nygaard, E.W. Jensen, J. Kvetny, A. Jarlov, J. Faber, Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur. J. Endocrinol. 161, 895–902 (2009). doi: 10.1530/eje-09-0542 CrossRefPubMedGoogle Scholar
- 10.P. Saravanan, D.J. Simmons, R. Greenwood, T.J. Peters, C.M. Dayan, Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J. Clin. Endocrinol. Metab. 90, 805–812 (2005). doi: 10.1210/jc.2004-1672 CrossRefPubMedGoogle Scholar
- 11.M. Valizadeh, M.R. Seyyed-Majidi, H. Hajibeigloo, S. Momtazi, N. Musavinasab, M.R. Hayatbakhsh, Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr. Res. 34, 80–89 (2009). doi: 10.1080/07435800903156340 CrossRefPubMedGoogle Scholar
- 12.V. Panicker, P. Saravanan, B. Vaidya, J. Evans, A.T. Hattersley, T.M. Frayling, C.M. Dayan, Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 94, 1623–1629 (2009). doi: 10.1210/jc.2008-1301 CrossRefPubMedGoogle Scholar
- 13.R.A. Philibert, S.R. Beach, T.D. Gunter, A.A. Todorov, G.H. Brody, M. Vijayendran, L. Elliott, N. Hollenbeck, D. Russell, C. Cutrona, The relationship of deiodinase 1 genotype and thyroid function to lifetime history of major depression in three independent populations. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B, 593–599 (2011). doi: 10.1002/ajmg.b.31200 CrossRefPubMedGoogle Scholar
- 14.B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26, 1–133 (2016). doi: 10.1089/thy.2015.0020 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.H. Jung, C.S. Ki, J.W. Kim, E.S. Kang, Frequencies of 10 autosomal minor histocompatibility antigens in Korean population and estimated disparities in unrelated hematopoietic stem cell transplantation. Tissue. Antigens. 79, 42–49 (2012). doi: 10.1111/j.1399-0039.2011.01810.x CrossRefPubMedGoogle Scholar
- 18.J.E. Ware Jr., B. Gandek, M. Kosinski, N.K. Aaronson, G. Apolone, J. Brazier, M. Bullinger, S. Kaasa, A. Leplege, L. Prieto, M. Sullivan, K. Thunedborg, The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J. Clin. Epidemiol. 51, 1167–1170 (1998)CrossRefGoogle Scholar
- 20.S.M. Oh, K.J. Min, D.B. Park, A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. J. Korean Neuropsychiatr. Assoc. 38, 289–296 (1999)Google Scholar
- 24.V.A. Galton, E.T. Wood, E.A. StGermain, C.A. Withrow, G. Aldrich, G.M. StGermain, A.S. Clark, D.L. St Germain, Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. Endocrinology. 148, 3080–3088 (2007). doi: 10.1210/en.2006-1727 CrossRefPubMedGoogle Scholar
- 26.E.A. McAninch, S. Jo, N.Z. Preite, E. Farkas, P. Mohacsik, C. Fekete, P. Egri, B. Gereben, Y. Li, Y. Deng, M.E. Patti, C. Zevenbergen, R.P. Peeters, D.C. Mash, A.C. Bianco, Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. J. Clin. Endocrinol. Metab. 100, 920–933 (2015). doi: 10.1210/jc.2014-4092 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.M. Torlontano, C. Durante, I. Torrente, U. Crocetti, G. Augello, G. Ronga, T. Montesano, L. Travascio, A. Verrienti, R. Bruno, S. Santini, P. D’Arcangelo, B. Dallapiccola, S. Filetti, V. Trischitta, Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J. Clin. Endocrinol. Metab. 93, 910–913 (2008). doi: 10.1210/jc.2007-1067 CrossRefPubMedGoogle Scholar
- 28.M.G. Castagna, M. Dentice, S. Cantara, R. Ambrosio, F. Maino, T. Porcelli, C. Marzocchi, C. Garbi, F. Pacini, D. Salvatore, DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J. Clin. Endocrinol. Metab. (2017). doi: 10.1210/jc.2016-2587 CrossRefGoogle Scholar
- 29.H.J. Wouters, H.C. van Loon, M.M. van der Klauw, M.F. Elderson, S.N. Slagter, A.M. Kobold, I.P. Kema, T.P. Links, J.V. van Vliet-Ostaptchouk, B.H. Wolffenbuttel, No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid. 27, 147–155 (2017). doi: 10.1089/thy.2016.0199 CrossRefPubMedGoogle Scholar
- 30.W.M. van der Deure, P.S. Hansen, R.P. Peeters, A.G. Uitterlinden, M. Fenger, K.O. Kyvik, L. Hegedus, T.J. Visser, The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins. Clin. Endocrinol. 70, 954–960 (2009). doi: 10.1111/j.1365-2265.2008.03420.x CrossRefGoogle Scholar
- 32.B.C. Appelhof, R.P. Peeters, W.M. Wiersinga, T.J. Visser, E.M. Wekking, J. Huyser, A.H. Schene, J.G. Tijssen, W.J. Hoogendijk, E. Fliers, Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3’-triiodothyronine therapy. J. Clin. Endocrinol. Metab. 90, 6296–6299 (2005). doi: 10.1210/jc.2005-0451 CrossRefPubMedGoogle Scholar
- 33.R. Cooper-Kazaz, W.M. van der Deure, M. Medici, T.J. Visser, A. Alkelai, B. Glaser, R.P. Peeters, B. Lerer, Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J. Affect. Disord. 116, 113–116 (2009). doi: 10.1016/j.jad.2008.10.019 CrossRefPubMedGoogle Scholar
- 35.V. Panicker, C. Cluett, B. Shields, A. Murray, K.S. Parnell, J.R. Perry, M.N. Weedon, A. Singleton, D. Hernandez, J. Evans, C. Durant, L. Ferrucci, D. Melzer, P. Saravanan, T.J. Visser, G. Ceresini, A.T. Hattersley, B. Vaidya, C.M. Dayan, T.M. Frayling, A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J. Clin. Endocrinol. Metab. 93, 3075–3081 (2008). doi: 10.1210/jc.2008-0397 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.B. He, J. Li, G. Wang, W. Ju, Y. Lu, Y. Shi, L. He, N. Zhong, Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog. Neuropsychopharmacol. Biol. Psychiatry. 33, 986–990 (2009). doi: 10.1016/j.pnpbp.2009.05.003 CrossRefPubMedGoogle Scholar